首页> 美国卫生研究院文献>Cancer Science >Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection
【2h】

Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection

机译:分支滚环扩增法测量血清循环微RNA水平以早期检测乳腺癌

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Serum circulating microRNAs (c‐miRNAs) are serving as useful biomarkers for cancer diagnosis. Here, we describe the development of a one‐step branched rolling circle amplification (BRCA) method to measure serum c‐miRNAs levels for early diagnosis of breast cancer. Four c‐miRNAs, c‐miRNA16 (c‐miR‐16), c‐miRNA21 (c‐miR‐21), c‐miRNA155 (c‐miR‐155), and c‐miRNA195 (c‐miR‐195) were isolated from the serum of 49 breast cancer patients (stages I‐IV) and 19 healthy controls, and analyzed using one‐step BRCA. The serum levels of c‐miR16, c‐miR21, c‐miR155, and c‐miR195 were higher (P < 0.0001) in stage I breast cancer patients than healthy controls. These levels were also higher in several breast cancer molecular subtypes (HER‐2 over‐expression, Luminal A, Luminal B, and triple negative breast cancer) than in healthy control subjects. The diagnostic accuracy of c‐miR16, c‐miR21, c‐miR155, and c‐miR195 for early diagnosis of breast cancer was confirmed by receiver operating characteristic (ROC) curve assay. These results show that the BRCA method can be used to measure serum c‐miRNAs levels, and that this method has high accuracy, sensitivity, and specificity. Moreover, both BRCA approach and quantitative real‐time style="fixed-case">PCR ( style="fixed-case">qRT‐ style="fixed-case">PCR) method show that the serum levels of c‐miR16, c‐miR21, c‐miR155, and c‐miR195 could be used as biomarkers to improve the early diagnosis of breast cancer, and distinguish different breast cancer molecular subtypes.
机译:血清循环微RNA(c-miRNA)可作为诊断癌症的有用生物标记。在这里,我们描述了一步式分支滚环扩增(BRCA)方法的发展,该方法可测量血清c-miRNA的水平以早期诊断乳腺癌。分别使用了四个c-miRNA,c-miRNA16(c-miR-16),c-miRNA21(c-miR-21),c-miRNA155(c-miR-155)和c-miRNA195(c-miR-195)。从49例乳腺癌患者的血清中分离(I-IV期)和19个健康对照,然后使用一步式BRCA进行分析。 I期乳腺癌患者的c-miR16,c-miR21,c-miR155和c-miR195的血清水平高于健康对照组(P <0.0001)。在某些乳腺癌分子亚型(HER-2过表达,Luminal A,Luminal B和三阴性乳腺癌)中,这些水平也较高。 c-miR16,c-miR21,c-miR155和c-miR195对乳腺癌的早期诊断的诊断准确性已通过接受者工作特征(ROC)曲线测定法得到了证实。这些结果表明,BRCA方法可用于测量血清c-miRNA水平,并且该方法具有很高的准确性,敏感性和特异性。此外,BRCA方法和定量实时 style =“ fixed-case”> PCR ( style =“ fixed-case”> qRT - style =“ fixed-case “> PCR )方法显示,血清c-miR16,c-miR21,c-miR155和c-miR195的水平可以用作生物标志物,以改善乳腺癌的早期诊断并区分不同的乳腺癌分子亚型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号